Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Lung Neoplasms 3Carcinoma, Renal Cell 3Recurrence 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumors 1Solid Tumor 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Neoplasms 1Multiple Myeloma 1Metastatic Urothelial Cancer 1

Interventions

pembrolizumab 14Nivolumab 11Ipilimumab 10cabozantinib 6Axitinib 6belzutifan 5Radiosurgery 5atezolizumab 4Sunitinib 4palbociclib 3lenvatinib 3Surveys and Questionnaires 3Radiotherapy 3Pluvicto 3Everolimus 3Blood Specimen Collection 3Biopsy 3zimberelimab 2pazopanib 2cemiplimab 2Therapeutics 2Methods 2Magnetic Resonance Spectroscopy 2Irinotecan 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2trebananib 1toripalimab 1tocilizumab 1temsirolimus 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Kidney Neoplasms × zimberelimab × 1 year × Clear all
NCT05536141 2026-06-01

ARC-20

Arcus Biosciences, Inc.

Phase 1 Recruiting
362 enrolled
Genitourinary

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡